Immediate Impact
2 from Science/Nature 58 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
New clinical trial design in precision medicine: discovery, development and direction
2024 Standout
Works of Ana Custodio being referenced
1098O Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)
2021
Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications
2011
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Ana Custodio | 684 | 318 | 293 | 297 | 73 | 1.1k | |
| Teresa Alonso‐Gordoa | 594 | 322 | 324 | 350 | 79 | 1.2k | |
| David Chan | 829 | 526 | 277 | 132 | 80 | 1.2k | |
| Vito Amoroso | 695 | 188 | 335 | 149 | 70 | 1.1k | |
| Ruža Arsenić | 469 | 437 | 214 | 225 | 53 | 1.1k | |
| Libero Ciuffreda | 768 | 211 | 267 | 288 | 62 | 1.3k | |
| Sukhmani K. Padda | 701 | 134 | 620 | 359 | 93 | 1.4k | |
| Ryuhei Tateishi | 516 | 405 | 422 | 360 | 56 | 1.4k | |
| Ferdinando Riccardi | 589 | 277 | 289 | 185 | 76 | 855 | |
| Limei Qu | 326 | 193 | 270 | 207 | 63 | 875 | |
| Javier Molina‐Cerrillo | 368 | 130 | 284 | 328 | 67 | 905 |
All Works
Login with ORCID to disown or claim papers
Loading papers...